These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38290608)

  • 1. Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A  Primary Immune Deficiency Treatment Consortium study.
    Grunebaum E; Arnold DE; Logan B; Parikh S; Marsh RA; Griffith LM; Mallhi K; Chellapandian D; Lim SS; Deal CL; Kapoor N; Murguía-Favela L; Falcone EL; Prasad VK; Touzot F; Bleesing JJ; Chandrakasan S; Heimall JR; Bednarski JJ; Broglie LA; Chong HJ; Kapadia M; Prockop S; Dávila Saldaña BJ; Schaefer E; Bauchat AL; Teira P; Chandra S; Parta M; Cowan MJ; Dvorak CC; Haddad E; Kohn DB; Notarangelo LD; Pai SY; Puck JM; Pulsipher MA; Torgerson TR; Malech HL; Kang EM; Leiding JW
    J Allergy Clin Immunol; 2024 May; 153(5):1423-1431.e2. PubMed ID: 38290608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT.
    Marsh RA; Leiding JW; Logan BR; Griffith LM; Arnold DE; Haddad E; Falcone EL; Yin Z; Patel K; Arbuckle E; Bleesing JJ; Sullivan KE; Heimall J; Burroughs LM; Skoda-Smith S; Chandrakasan S; Yu LC; Oshrine BR; Cuvelier GDE; Thakar MS; Chen K; Teira P; Shenoy S; Phelan R; Forbes LR; Chellapandian D; Dávila Saldaña BJ; Shah AJ; Weinacht KG; Joshi A; Boulad F; Quigg TC; Dvorak CC; Grossman D; Torgerson T; Graham P; Prasad V; Knutsen A; Chong H; Miller H; de la Morena MT; DeSantes K; Cowan MJ; Notarangelo LD; Kohn DB; Stenger E; Pai SY; Routes JM; Puck JM; Kapoor N; Pulsipher MA; Malech HL; Parikh S; Kang EM;
    J Clin Immunol; 2019 Oct; 39(7):653-667. PubMed ID: 31376032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic Cell Transplantation for Chronic Granulomatous Disease in Japan.
    Yanagimachi M; Kato K; Iguchi A; Sasaki K; Kiyotani C; Koh K; Koike T; Sano H; Shigemura T; Muramatsu H; Okada K; Inoue M; Tabuchi K; Nishimura T; Mizukami T; Nunoi H; Imai K; Kobayashi M; Morio T
    Front Immunol; 2020; 11():1617. PubMed ID: 32849547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of allogeneic hematopoietic stem cell transplantation for chronic granulomatous disease in children: A multicentre, retrospective cohort study in China.
    Si Y; Dou Y; Zhai X; Zhou C; Lu W; Meng Y; Qian X; Chen J; Wang P; Luo C; Yu J; Tang X
    Clin Immunol; 2024 Mar; 260():109919. PubMed ID: 38309448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
    Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD.
    Leiding JW; Arnold DE; Parikh S; Logan B; Marsh RA; Griffith LM; Wu R; Kidd S; Mallhi K; Chellapandian D; Si Lim SJ; Grunebaum E; Falcone EL; Murguia-Favela L; Grossman D; Prasad VK; Heimall JR; Touzot F; Burroughs LM; Bleesing J; Kapoor N; Dara J; Williams O; Kapadia M; Oshrine BR; Bednarski JJ; Rayes A; Chong H; Cuvelier GDE; Forbes Satter LR; Martinez C; Vander Lugt MT; Yu LC; Chandrakasan S; Joshi A; Prockop SE; Dávila Saldaña BJ; Aquino V; Broglie LA; Ebens CL; Madden LM; DeSantes K; Milner J; Rangarajan HG; Shah AJ; Gillio AP; Knutsen AP; Miller HK; Moore TB; Graham P; Bauchat A; Bunin NJ; Teira P; Petrovic A; Chandra S; Abdel-Azim H; Dorsey MJ; Birbrayer O; Cowan MJ; Dvorak CC; Haddad E; Kohn DB; Notarangelo LD; Pai SY; Puck JM; Pulsipher MA; Torgerson TR; Malech HL; Kang EM
    Blood; 2023 Dec; 142(24):2105-2118. PubMed ID: 37562003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.
    Morillo-Gutierrez B; Beier R; Rao K; Burroughs L; Schulz A; Ewins AM; Gibson B; Sedlacek P; Krol L; Strahm B; Zaidman I; Kalwak K; Talano JA; Woolfrey A; Fraser C; Meyts I; Müller I; Wachowiak J; Bernardo ME; Veys P; Sykora KW; Gennery AR; Slatter M
    Blood; 2016 Jul; 128(3):440-8. PubMed ID: 27216217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic Hematopoietic Cell Transplantation for Chronic Granulomatous Disease: Controversies and State of the Art.
    Connelly JA; Marsh R; Parikh S; Talano JA
    J Pediatric Infect Dis Soc; 2018 May; 7(suppl_1):S31-S39. PubMed ID: 29746680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults.
    Chiesa R; Wang J; Blok HJ; Hazelaar S; Neven B; Moshous D; Schulz A; Hoenig M; Hauck F; Al Seraihy A; Gozdzik J; Ljungman P; Lindemans CA; Fernandes JF; Kalwak K; Strahm B; Schanz U; Sedlacek P; Sykora KW; Aksoylar S; Locatelli F; Stepensky P; Wynn R; Lum SH; Zecca M; Porta F; Taskinen M; Gibson B; Matthes S; Karakukcu M; Hauri-Hohl M; Veys P; Gennery AR; Lucchini G; Felber M; Albert MH; Balashov D; Lankester A; Güngör T; Slatter MA
    Blood; 2020 Sep; 136(10):1201-1211. PubMed ID: 32614953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic Hematopoietic Cell Transplantation in Patients with Primary Immunodeficiencies in Korea: Eleven-Year Experience in a Single Center.
    Yi ES; Choi YB; Lee NH; Lee JW; Sung KW; Koo HH; Kang ES; Kim YJ; Yoo KH
    J Clin Immunol; 2018 Oct; 38(7):757-766. PubMed ID: 30151618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease.
    Martinez CA; Shah S; Shearer WT; Rosenblatt HM; Paul ME; Chinen J; Leung KS; Kennedy-Nasser A; Brenner MK; Heslop HE; Liu H; Wu MF; Hanson IC; Krance RA
    J Allergy Clin Immunol; 2012 Jan; 129(1):176-83. PubMed ID: 22078471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with a Reduced Toxicity Allogeneic Transplant Regimen for Non-CGD Primary Immune Deficiencies Requiring Myeloablation.
    Chandra S; Chandrakasan S; Dávila Saldaña BJ; Bleesing JJ; Jordan MB; Kumar AR; Grimley MS; Krupski C; Davies SM; Khandelwal P; Marsh RA
    J Clin Immunol; 2021 Jan; 41(1):89-98. PubMed ID: 33067658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
    Aldenhoven M; Jones SA; Bonney D; Borrill RE; Coussons M; Mercer J; Bierings MB; Versluys B; van Hasselt PM; Wijburg FA; van der Ploeg AT; Wynn RF; Boelens JJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1106-9. PubMed ID: 25708213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease--single centre experience.
    Goździk J; Pituch-Noworolska A; Skoczeń S; Czogała W; Wędrychowicz A; Baran J; Krasowska-Kwiecień A; Wiecha O; Zembala M
    J Clin Immunol; 2011 Jun; 31(3):332-7. PubMed ID: 21384251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Allogeneic Hematopoietic Stem Cell Transplant for Chronic Granulomatous Disease (CGD): a Report of the United States Immunodeficiency Network.
    Yonkof JR; Gupta A; Fu P; Garabedian E; Dalal J;
    J Clin Immunol; 2019 May; 39(4):448-458. PubMed ID: 31111420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
    Marsh RA; Bleesing JJ; Chandrakasan S; Jordan MB; Davies SM; Filipovich AH
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1641-5. PubMed ID: 24923536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity conditioning for hematopoietic cell transplantation of chronic granulomatous disease.
    Oshrine B; Morsheimer M; Heimall J; Bunin N
    Pediatr Blood Cancer; 2015 Feb; 62(2):359-361. PubMed ID: 25175046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.
    Seger RA; Gungor T; Belohradsky BH; Blanche S; Bordigoni P; Di Bartolomeo P; Flood T; Landais P; Müller S; Ozsahin H; Passwell JH; Porta F; Slavin S; Wulffraat N; Zintl F; Nagler A; Cant A; Fischer A
    Blood; 2002 Dec; 100(13):4344-50. PubMed ID: 12393596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic stem cell transplantation in children with chronic granulomatous disease: the Spanish experience.
    Alonso García L; Bueno Sánchez D; Fernández Navarro JM; Regueiro Garcia A; Blanquer Blanquer M; Benitez Carabante MI; Mozo Del Castillo Y; Fuster Soler JL; Uria Oficialdegui ML; Sisinni L; Perez Martinez A; Diaz de Heredia Rubio C
    Front Immunol; 2024; 15():1307932. PubMed ID: 38370416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.